Trial site
Eastside Research Associates
Redmond, Washington 98052, United StatesNot linked to an institution yet
- 14running trials
- 6closed trials
The trials here
What the 20 trials at this site are about, from their registry records.
- Phase
- Phase 316 trials
- Phase 22 trials
- Status
- Active, not recruiting8 trials
- Completed6 trials
- Recruiting4 trials
- Not yet recruiting2 trials
- Lead sponsor
- Eli Lilly and Company16 trials
- Crystalys Therapeutics2 trials
- Abbott Point of Care1 trial
- Hoffmann-La Roche1 trial
Running trials
Not yet recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
NCT07900633· Phase 3· Eli Lilly and Company· Source
Contact: Christopher Price (principal investigator)
Recruiting
A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT07881458· Phase 3· Eli Lilly and Company· Source
Contact: Christopher Price (principal investigator)
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593· Phase 3· Eli Lilly and Company· Source
Contact: Christopher Price (principal investigator)
Recruiting
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
NCT07089888· Phase 3· Crystalys Therapeutics· Source
Contact: Christopher Price, MD
Recruiting
A Study of Dotinurad Versus Allopurinol in Participants With Gout
NCT07089875· Phase 3· Crystalys Therapeutics· Source
Contact: Christopher Price, MD
Active, not recruiting
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
NCT06948422· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
NCT06952530· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895· Phase 3· Eli Lilly and Company· Source
Recruiting
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
NCT06897475· Phase 2· Eli Lilly and Company· Source
Contact: Chad Crystal (principal investigator)
Active, not recruiting
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
NCT06643728· Phase 2· Eli Lilly and Company· Source
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512· Phase 3· Eli Lilly and Company· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error